Product nameAnti-IKK alpha antibody [Y463] (HRP)
See all IKK alpha primary antibodies
DescriptionRabbit monoclonal [Y463] to IKK alpha (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic peptide within Human IKK alpha aa 1-100 (N terminal). The exact sequence is proprietary.
- WB: Daudi and HeLa cell lysate.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% Proclin
Constituents: PBS, 30% Glycerol, 1% BSA
Concentration information loading...
- Anti-IKK alpha antibody [Y463] - BSA and Azide free (ab169743)
- Anti-IKK alpha antibody [Y463] (Alexa Fluor® 488) (ab200412)
- Anti-IKK alpha antibody [Y463] (Alexa Fluor® 647) (ab200414)
- Anti-IKK alpha antibody [Y463] (Phycoerythrin) (ab210716)
- Anti-IKK alpha antibody [Y463] (Allophycocyanin) (ab221910)
- Anti-IKK alpha antibody [Y463] (ab32041)
Our Abpromise guarantee covers the use of ab200415 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 88 kDa (predicted molecular weight: 85 kDa).|
FunctionActs as part of the IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. Also phosphorylates NCOA3. Phosphorylates 'Ser-10' of histone H3 at NF-kappa-B-regulated promoters during inflammatory responses triggered by cytokines.
Tissue specificityWidely expressed.
Involvement in diseaseDefects in CHUK are the cause of cocoon syndrome (COCOS) [MIM:613630]; also known as fetal encasement syndrome. COCOS is a lethal syndrome characterized by multiple fetal malformations including defective face and seemingly absent limbs, which are bound to the trunk and encased under the skin.
Sequence similaritiesBelongs to the protein kinase superfamily. Ser/Thr protein kinase family. I-kappa-B kinase subfamily.
Contains 1 protein kinase domain.
modificationsPhosphorylated by MAP3K14/NIK, AKT and to a lesser extent by MEKK1, and dephosphorylated by PP2A. Autophosphorylated.
Acetylation of Thr-179 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the I-kappa-B signaling pathway.
Cellular localizationCytoplasm. Nucleus. Shuttles between the cytoplasm and the nucleus.
- Information by UniProt
- chuk antibody
- CHUK1 antibody
- Conserved Helix Loop Helix Ubiquitous Kinase antibody
All lanes : Anti-IKK alpha antibody [Y463] (HRP) (ab200415) at 1/5000 dilution
Lane 1 :
Daudi whole cell lysate (ab3951)
Lane 2 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate (ab27252)
Lane 3 : Hap1 WT
Lane 4 : IKK alpha knockout HAP1 cell lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 85 kDa
Observed band size: 88 kDa why is the actual band size different from the predicted?
Exposure time: 8 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab200415 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab200415 has not yet been referenced specifically in any publications.